Newsletter | January 27, 2025

01.27.25 -- Terran Biosciences' 2025 Prodrug Outlook

SPONSOR

A Full-Service Solution Partner Disrupting the Outsourcing Paradigm

inSeption Group offers a full-service solution designed to disrupt the current outsourcing paradigm, resurrecting a common-sense approach to rebuild business trust and confidence in a client’s selected vendor. Primarily focused on oncology, hematology, neurodegenerative disorders, and rare/orphan disease indications, with a specialization in cell and gene therapy, inSeption has been a solution for its’ clients who have experienced the progressive degradation of today’s outsourcing options. Contact them.

FEATURED VIDEO

Terran Biosciences' 2025 Prodrug Outlook

Terran Biosciences' founder and CEO Sam Clark talks about big opportunities for prodrug development in 2025, the importance of a strong medicinal chemistry team, and a potential increase in M&A activity this year.

INDUSTRY INSIGHTS

5 Common Misconceptions About Mobile Visits In Clinical Trials

In this article, we address five key misconceptions about mobile research services, including concerns about inconsistent nurse assignments, privacy risks, and limited applications for complex protocols.

Key Analytical Considerations For Developing A Clinical AAV Program

Unlike traditional drugs, AAV therapies require extensive characterization and testing, demanding varying degrees of analysis at each stage of development.

A Data-Driven Exploration Of Decentralized Elements, Digital Tech

Discover how industry leaders are driving change, accelerating clinical research, and transforming patient care in the era of digital innovation.

Machine Learning To Drive Clinical Trial Efficiency

Authors explore accessing real-time clinical trial data for proactive study management, using adverse event data to enhance safety and performance, and tools to improve design.